Standard versus restricted fluid administration in preterm infants undergoing pharmacological treatment for haemodynamically significant patent ductus arteriosus

The article suggests that fluid restriction does not improve the response to pharmacological treatment for PDA, but could negatively influence growth of preterm infants before discharge, which might have long term repercussions. It highlights there is no benefit, but potential harm, of fluid restriction to promote PDA in this vulnerable population. The findings could guide changes in clinical practice, improving PDA management and potentially reducing complications for preterm infants who are highly sensitive to fluid imbalances. The study advocates for further clinical trials to explore the optimal hydration strategies in managing PDA, paving the way for future research that can refine and standardize treatment protocols.